Kyverna disclosed registrational‑quality trial results for its CD19 CAR‑T in stiff person syndrome (SPS), showing statistically robust improvements in mobility and symptom endpoints. The company said it will seek U.S. regulatory clearance, targeting a first‑half‑2026 filing, positioning Kyverna to pursue the first FDA approval of a CAR‑T therapy for an autoimmune disorder. The readouts were described by company executives and clinical investigators as highly significant across primary and secondary measures.